Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma

Br J Haematol. 2020 Aug;190(3):305. doi: 10.1111/bjh.16663. Epub 2020 Apr 22.

Authors

Marquita Camilleri¹, Huw Richards¹, Sabine Pomplun², Andrew Wilson¹, Anna Checkley³, Neil Rabin¹

Affiliations

¹ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
² Department of Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
³ Department of Infectious Diseases and Tropical Medicine, University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 32323306
DOI: 10.1111/bjh.16663

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antiprotozoal Agents / therapeutic use
Combined Modality Therapy
Drug Substitution
Endemic Diseases
Humans
Immunocompromised Host
Immunomodulation*
Leishmania donovani
Leishmaniasis, Visceral / complications*
Leishmaniasis, Visceral / drug therapy
Leishmaniasis, Visceral / parasitology
Lenalidomide / adverse effects*
Male
Mediterranean Region
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy
Multiple Myeloma / therapy
Pancytopenia / etiology*
Pancytopenia / pathology
Phosphorylcholine / analogs & derivatives
Phosphorylcholine / therapeutic use
Recurrence
Renal Dialysis
Travel-Related Illness*

Substances

Antiprotozoal Agents
Phosphorylcholine
miltefosine
Lenalidomide